Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.11.18 (
MAP
)
7,412
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dual specificity phosphatase 1
(
DUSP1
) dephosphorylates and, hence, regulates the activity of
MAP
kinases. The present study investigated the effect of
DUSP1
on inflammatory gene expression and on the development of carrageenan-induced inflammation. It was found that
DUSP1
expression was increased by LPS, and the down-regulation of
DUSP1
by siRNA enhanced the phosphorylation of p38 MAPK, while JNK phosphorylation was not affected in murine macrophages. LPS-induced interleukin (IL)-6, tumor-necrosis factor (TNF) and cyclooxygenase-2 (COX2) expression were enhanced in bone marrow-derived macrophages (BMMs) from
DUSP1
(-/-) mice as compared to those from wild-type mice. In addition, down-regulation of
DUSP1
by siRNA enhanced IL-6, TNF and COX2 expression in J774 macrophages, while p38 MAPK inhibitors SB202190 and BIRB 796 inhibited the expression of those inflammatory factors. In vivo, the intensity of the carrageenan-induced paw edema reaction was increased in
DUSP1
(-/-) mice as compared to the wild-type animals. In conclusion,
DUSP1
is an important negative regulator of the acute inflammatory response by limiting p38 MAPK, and compounds which enhance
DUSP1
expression or activity may hold a promise as anti-inflammatory drugs.
...
PMID:Attenuation of the acute inflammatory response by dual specificity phosphatase 1 by inhibition of p38 MAP kinase. 2176 56
